Infinity pharmaceuticals, inc. (INFI)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Operating activities
Net loss

-47,057

-11,253

-41,830

-30,101

-128,376

-17,416

-126,780

-53,964

-40,042

-48,984

-31,278

Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash gain on AbbVie Opt-Out (note 11)

-

-

-

112,216

0

0

-

-

-

-

-

Note payable (note 10)

-

-

6,000

0

0

-

-

-

-

-

-

Depreciation

219

191

1,715

3,418

2,292

1,773

1,823

1,643

2,099

2,184

2,153

Stock-based compensation, including 401(k) match

-

-

-

-

-

12,588

12,155

7,811

5,441

7,883

7,037

Stock-based compensation

2,133

3,448

6,972

13,714

14,700

-

-

-

-

-

-

Non-cash royalty revenue

555

0

-

-

-

-

-

-

-

-

-

Non-cash interest expense

2,600

0

-

-

-

-

-

-

-

-

-

Gain (Loss) on Termination of Lease

-

-

-1,900

0

0

-

-

-

-

-

-

Impairment of property and equipment

-

-

-

771

0

0

-

-

-

-

-

Gain (Loss) on Disposition of Property Plant Equipment

-

-

736

876

0

0

-

-

-

-

79

Non-cash interest expense on amount Due to Takeda

-

-

-

-

-

211

-

-

-

-

-

Non-cash interest expense on long-term debt due to Purdue entities

-

-

-

-

-

-

-

1,908

102

-

-

Non-cash interest expense on Due to Takeda amount

-

-

-

-

-

-

415

-

-

-

-

Gain on sale of available-for-sale securities

-

-

-

-

-

-

-

-

-

-

28

Amortization of loan commitment asset

-

-

-

0

647

9,649

-

-

1,588

1,732

1,298

Net amortization of premium/discount on available-for-sale securities

-

-

-

-159

-272

-1,257

-2,201

-1,653

-915

-1,496

-129

Impairment of available-for-sale securities

-

-

-

-

-

-

-

-

-

-

15

Impairment of property and equipment

-

-

-

-

-

-

-

161

-

311

-

Other, net

216

-138

25

2

162

-83

2

-46

-72

-80

-60

Changes in operating assets and liabilities:
Unbilled accounts receivable

-

-

-

-

-

-

-

-218

218

-

-

Unbilled accounts receivable

-

-

-

-

-

-

-

-

-

-

-7,414

Prepaid expenses and other assets

756

71

-7,110

-5,208

-933

494

7,284

1,037

-356

-599

1,075

Operating lease right-of-use assets

-364

-

-

-

-

-

-

-

-

-

-

Accounts payable, accrued expenses and other liabilities

1,550

2,833

-17,799

-15,708

11,774

6,815

3,565

-12,395

1,359

11,762

-4,380

Operating lease liability

225

-

-

-

-

-

-

-

-

-

-

Due to Takeda

-

-

-

0

-6,667

-6,667

-

-

-

-

-

Due to Takeda

-

-

-

-

-

-

-

12,708

-

-

-

Deferred revenue

-

-

-

-18,723

20,934

110,005

-

-38,887

-

-

-

Deferred rent

-

-

-

-

-

-89

-

-

-

-

-

Net cash used in operating activities

-

-

-

-154,356

-83,653

117,715

-113,907

-80,135

-

-

-

Deferred revenue from Purdue entities

-

-

-

-

-

-

-

-

-4,781

-3,648

13,974

Net cash used in operating activities

-41,530

-4,714

-36,711

-

-

-

-

-

-33,109

-26,585

-4,756

Investing activities
Purchases of property and equipment

2,327

0

43

661

6,426

1,362

1,754

1,301

1,542

1,949

2,527

Proceeds from sale of assets

-

-

750

2,140

0

-

-

-

-

-

-

Proceeds from sale of assets

-

-

-

-

-

0

-

-

-

-

79

Purchases of available-for-sale securities

41,864

15,686

23,985

66,503

121,456

21,789

249,764

180,498

150,588

201,095

166,565

Proceeds from maturities of available-for-sale securities

31,950

28,790

19,000

93,400

89,515

141,004

251,093

113,520

137,153

226,284

125,375

Proceeds from sales of available-for-sale securities

-

-

-

11,953

464

0

1,031

6,281

1,289

7,240

36,141

Net cash provided by (used in) investing activities

-

-

-

40,329

-37,903

117,853

606

-61,998

-

-

-

Net cash provided by (used in) investing activities

-12,241

13,104

-4,278

-

-

-

-

-

-13,688

30,480

-7,496

Financing activities
Proceeds from sale of future royalties, net

27,618

0

-

-

-

-

-

-

-

-

-

Borrowings of long-term debt from Purdue entities

-

-

-

-

-

-

-

-

50,000

-

-

Proceeds from issuance of common stock to Purdue entities

-

-

-

-

-

-

-

-

-

-

11,830

Proceeds from common stock sales facility, net of issuance costs

0

9,330

0

-

-

-

-

244,792

-

-

201

Proceeds from issuances of common stock, net

112

289

146

-

-

-

-

-

-

-

-

Repayment of note payable

0

4,000

0

-

-

-

-

-

-

-

-

Proceeds from issuances of common stock, net

-

-

-

332

2,830

836

374

-

-

-

-

Payments on construction liability

-

-

-

0

273

0

-

-

-

-

-

Payments on financing obligation

-

-

292

415

236

0

-

-

-

-

-

Proceeds from issuance of common stock to Purdue entities

-

-

-

-

-

-

-

27,500

-

-

-

Proceeds from issuances of common stock related to stock incentive plans and awards

-

-

-

-

-

3,881

5,299

21,386

582

-

-

Restricted cash

-

-

-

0

0

-548

-

-

-

-

-

Deferred transaction costs

-

-

-

-

-

446

-

-

-

-

-

Net cash provided by (used in) financing activities

-

-

-

-83

2,321

3,723

5,673

293,678

-

-

-

Other financing activities

-

-

-

-

-

-

-

-

-5

10

-

Proceeds from issuances of common stock related to stock incentive plans

-

-

-

-

-

-

-

-

-

225

-

Capital lease payments

-

-

-

-

-

-

-

-

-

-

5

New employee loans

-

-

-

-

-

-

-

-

-

-

60

Net cash provided by financing activities

27,730

5,619

-146

-

-

-

-

-

50,577

235

11,965

Net increase in cash, cash equivalents and restricted cash

-26,041

14,009

-41,135

-

-

-

-

-

-

-

-

Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets
Net decrease in cash and cash equivalents

-

-

-

-114,110

-119,235

239,291

-107,628

151,545

3,780

4,130

-287

Cash paid for interest

-

-

802

-

-

-

-

-

-

-

-

Cash paid for income taxes

-

-

-

5

885

0

-

-

-

-

75

Supplemental schedule of noncash activities
Cash paid for interest

-

-

-

1,225

721

0

-

-

-

-

-

Supplemental schedule of noncash activities
Assets acquired under operating lease obligation

1,908

-

-

-

-

-

-

-

-

-

-

Receivable for stock option exercises

-

-

-

-

-

-

152

200

-

-

-

Loan commitment asset

-

-

-

-

-

9,850

-

-

-

-

-

Facility fee

-

-

-

-

-

1,500

-

-

-

-

-

Warrants issued

-

-

-

-

-

8,350

-

-

-

-

-

Reclassification to financing obligation

-

-

-

0

19,273

0

-

-

-

-

-

Property and equipment in accounts payable and accrued expenses

50

0

-

0

65

0

-

-

-

-

-

Issuance of common stock for repayment of note payable, including interest

0

2,301

0

-

-

-

-

-

-

-

-

Issuance of common stock for compensation

0

493

0

-

-

-

-

-

-

-

-

Increase in property and equipment for amount paid by landlord

-

-

-

0

5,059

797

-

-

-

-

-

Issuance of common stock to extinguish debt from Purdue entities

-

-

-

-

-

-

-

51,277

-

-

-